CPNG Coupang Cut Its Full-Year Loss 94% - So Why Did the Stock Fall 50%?

A Nearly-Breakeven Year Built Almost Entirely in One Quarter

Coupang's full-year 2022 net loss came in at $(92.0) million - down 94% from $(1,542.6) million in 2021, and close enough to breakeven that a skimming reader could mistake it for the company having basically turned the corner across the whole year. It didn't, not evenly. Q3 2022 already delivered Coupang's first-ever profitable quarter ($90.7 million net income) and first-ever positive operating income ($77.4 million). This filing's full-year total, compared against the nine-month figure already reported on this site ($(194.1) million net loss through September), implies Q4 2022 alone earned roughly $102.1 million of net income - not just holding onto Q3's breakthrough but beating it, in the seasonally biggest quarter of the year. Adjusted EBITDA tells the same story: full-year $381.2 million (margin 1.9%, reversing a $(747.6) million loss in 2021) implies Q4 Adjusted EBITDA of roughly $211.0 million, again ahead of Q3's $194.9 million. Two consecutive quarters of accelerating profitability, now stacked on top of each other, is a fundamentally different signal than a single profitable quarter that could have been a one-off.

And yet the stock closed 2022 at $14.71, down 49.9% for the full year from $29.38 at the end of 2021 - and down a further 11.8% in Q4 alone, from $16.67 at the end of Q3, despite Q4 being the best quarter Coupang has ever reported as a public company. This is the real tension of this filing: operationally, 2022 ended with two straight quarters of record profitability and a full-year loss that essentially rounds to zero; financially, the market priced the stock as if none of that mattered, continuing a decline that had already decoupled from operating results back in Q1 2022. Q3's post noted that quarter was the first time operating improvement and share price moved together - Q4 reverses that alignment again, and this filing itself surfaces a new reason a market might be pricing in caution beyond pure macro sentiment (see Beyond the Usual below).

The Prescription

Coupang should put its now-genuinely-deleveraged balance sheet to work signaling capital-allocation discipline, not just operating discipline. Total principal long-term debt fell to $670.2 million at December 31, 2022 from $626.2 million a year earlier - but that understates the story: this site's Q3 2022 post recorded principal long-term debt at $1.721 billion as of September 30, 2022, meaning Coupang repaid a large chunk of its own construction-loan debt in the fourth quarter alone (full-year repayment of long-term debt was $446.4 million, more than double 2021's $169.6 million). Combined with net cash of roughly $2.7 billion and Q4's strongly positive free cash flow, Coupang now has real capacity to either buy back stock at a multiple the market itself is compressing, or fund fulfillment-center growth without more secured borrowing - either would be a credible answer to "the market doesn't believe the operating improvement is real," which is exactly what a 50% annual share-price decline against a 94% loss reduction implies investors currently think.

What it should stop doing: taking on new secured facilities in the same year it's telling the deleveraging story above. In September 2022, Coupang entered an $87 million one-year term loan secured by $104 million of pledged land, and in October 2022 added a two-year, $126 million revolving facility secured by $615 million of inventories - both layered on top of the big Q4 debt paydown, and both increasing total pledged land and buildings collateral to $974 million by year-end (from $861 million at the end of Q3). Simultaneously paying down $446 million of debt and adding new secured facilities sends a mixed signal about whether the deleveraging is a deliberate strategy or just debt being refinanced from one form into another - Coupang should pick one narrative and be consistent about it.

Key Financial Metrics

Full-year 2022 vs. full-year 2021, consolidated - reported in USD

Coupang reports natively in US dollars, so no FX conversion is needed here. Figures are drawn directly from this 10-K's consolidated financial statements and MD&A tables, covering the fiscal year ended December 31, 2022 - Coupang's second Annual Report on Form 10-K as a public company.

Metric	FY2022	FY2021	YoY
Total net revenues	$20,582.6M	$18,406.4M	✅ +12% (+26% constant currency)
Gross profit	$4,709.9M	$2,951.1M	✅ +60%, margin 22.9% vs 16.0%
Operating income (loss)	$(112.0)M	$(1,494.0)M	✅ -93% narrower, margin -0.5% vs -8.1%
Adjusted EBITDA»	$381.2M	$(747.6)M	✅ first-ever positive full year, margin 1.9% vs -4.1%
Net income (loss)	$(92.0)M	$(1,542.6)M	✅ -94% narrower, margin -0.4% vs -8.4%
Net cash provided by (used in) operating activities	$565.4M	$(410.6)M	✅ swung positive
Free cash flow»	$(245.6)M	$(1,082.4)M	✅ outflow narrowed 77%
Cash & cash equivalents (period end)	$3,509.3M	$3,487.7M	✅ +0.6%

Implied Q4 2022 standalone figures (this site's own calculation - full-year total minus the nine-month figures already reported): revenue approximately $5,326.8 million, operating income approximately $83.4 million (a second straight positive quarter, ahead of Q3's $77.4 million), net income approximately $102.1 million (also ahead of Q3's $90.7 million), and Adjusted EBITDA approximately $211.0 million (ahead of Q3's $194.9 million). Free cash flow swung to an implied positive $461.9 million in Q4 alone - a sharp reversal from three straight quarters of triple-digit-million outflows, consistent with the working-capital dynamics of a holiday-season peak quarter (higher payables, faster inventory turns) rather than a change in the underlying capex trajectory.

Balance sheet metric	Dec 2022	Dec 2021	Change
Total assets	$9,512.9M	$8,641.8M	✅ +10.1%
Total liabilities	$7,099.0M	$6,465.9M	⚠️ +9.8%
Total stockholders' equity	$2,413.9M	$2,176.0M	✅ +10.9%

Both sides of the balance sheet grew at a similar pace, so leverage as a share of the balance sheet didn't meaningfully worsen - equity actually grew slightly faster than liabilities. This is a different read from mid-2022, when Q3's post flagged total assets shrinking while Coupang built up debt; by year-end, the balance sheet had grown again on the strength of retained cash generation rather than fresh borrowing (see The Prescription above on the debt paydown itself).

Segment Performance: Product Commerce vs. Developing Offerings

Coupang reports two segments, the same structure as Q3 2022: Product Commerce (core retail, marketplace, Rocket Fresh, and related advertising) and Developing Offerings (Coupang Eats, Coupang Play, international expansion, and fintech).

Metric	Product Commerce FY2022	Product Commerce FY2021	Developing Offerings FY2022	Developing Offerings FY2021
Net revenues	$19,954.6M	$17,837.7M	$628.0M	$568.7M
Revenue growth	✅ +12% (28% constant currency)	—	✅ +10% (25% constant currency)	—
Segment Adjusted EBITDA	✅ $605.8M	$(360.9)M	✅ $(224.6)M	$(386.7)M

Product Commerce swung from a $(360.9) million Segment Adjusted EBITDA loss to a $605.8 million profit for the full year - the segment that Q2 2022's post questioned as possibly benefiting from an undisclosed fire-comp allocation, and that Q3's post confirmed was genuinely turning profitable on a clean comparison basis. The full-year number puts that question to rest for good: this is now a consistently, substantially profitable core retail business, not a quarter-to-quarter swing story.

Developing Offerings narrowed its loss 42% for the full year, to $(224.6) million from $(386.7) million, on 10% revenue growth (25% constant currency) - a smaller-magnitude improvement than Product Commerce's, but moving the same direction all year. Unlike Product Commerce, this segment is still solidly loss-making even after the improvement, and its revenue growth rate (10% reported) trails Product Commerce's (12% reported) for the full year, a reversal of the segment's earlier-2022 pattern of outgrowing the core business - worth watching whether Developing Offerings is settling into a smaller, steadier drag or genuinely approaching breakeven at its current scale.

Key Operational Metrics

Metric	FY2022 (Dec 2022)	FY2021 (Dec 2021)	YoY
Active Customers	18.115M	17.936M	✅ +1.0%
Total net revenue per Active Customer	$294	$283	✅ +3.9%

Quarter	Active Customers	Revenue per Active Customer
Q4 2021	17.936M	$283
Q1 2022	18.112M	$283
Q2 2022	17.885M	$282
Q3 2022	17.992M	$284
Q4 2022	18.115M	$294

Active Customers closed 2022 at a new record of 18.115 million, but the more notable move is revenue per Active Customer, which jumped to $294 - a $10 sequential increase, the largest quarter-over-quarter jump in this metric this site has tracked, more than double any prior quarter's move. Q3's post noted both metrics hitting new highs together for the first time; Q4 pushes revenue per customer meaningfully further, consistent with the holiday-season spending typical of a Q4 for any retailer - a seasonal effect worth keeping in mind before assuming this $10 jump represents a new steady-state level rather than Q4's usual seasonal lift repeating what happened between Q3 2021's $276 and Q4 2021's $283.

"Not available" again this filing: orders per customer, Rocket WOW membership subscriber count, and third-party seller/merchant count - none disclosed, consistent with every prior quarter and filing.

Beyond the Usual

A securities class action over the IPO registration statement surfaced in this filing without appearing in any prior post

On August 26, 2022, a putative class action (Choi v. Coupang, Inc. et al) was filed in the U.S. District Court for the Southern District of New York on behalf of all purchasers of Coupang Class A common stock "pursuant and/or traceable to" the company's IPO registration statement, alleging inaccurate, misleading, or omitted statements of material fact in violation of Sections 11 and 15 of the Securities Act of 1933. The suit names Coupang, certain current and former directors and officers, and certain underwriters of the offering. No lead plaintiff has been named, no damages amount is specified, and Coupang states it believes the action is without merit and intends to defend against it - none of which resolves what the suit actually alleges: that the disclosures underpinning the company's own March 2021 IPO were themselves inaccurate or incomplete. This action was filed within Q3 2022 but never appeared in this site's Q3 2022 coverage; it's a live, unresolved matter as of this filing and worth tracking every quarter until it's dismissed or settled.

The Korean severance liability reversed its two-quarter decline, jumping back up by year-end

The defined severance benefits liability - tracked declining from $229.5 million (June 2022) to $222.2 million (September 2022) - reversed sharply to $304.5 million at December 31, 2022, a 37% jump from the September figure and above the $283.0 million level the liability started the year at. Unlike the actuarial-gain-driven declines flagged in earlier quarters, this jump is driven by ordinary business growth: $143.4 million of current service cost for the full year (from continued headcount additions) outweighed a $31.5 million actuarial gain and $81.1 million of payments made from the plan. A liability that moved for opposite reasons in consecutive quarters this year is a reminder that its direction alone doesn't tell a consistent story - the underlying driver needs checking each time.

Coupang repaid $446 million of long-term debt in 2022, more than double the prior year's repayment

Total repayment of long-term debt was $446.4 million for the full year 2022, more than double 2021's $169.6 million, and consistent with the sharp drop in principal long-term debt discussed in The Prescription above (from $1.721 billion at Q3 2022's quarter-end to $670.2 million at year-end). This is a genuine deleveraging move funded from operating cash flow, not a refinancing shuffle - though see the prescription section above for the tension between this and the same-year addition of new secured facilities.

Coupang received a $79 million refundable insurance advance for the 2021 fulfillment-center fire - still unresolved after 18 months

In December 2022, Coupang received a refundable cash advance of $79 million related to insurance claims from the June 2021 Deokpyeong fulfillment-center fire (the "FC Fire," first flagged in this site's Q2 2021 post). The advance is booked in other current liabilities rather than recognized as insurance income, because it remains refundable and Coupang has not recognized any insurance benefit in its results to date. Eighteen months after a $296 million loss event, the company still doesn't know how much of it insurance will ultimately cover.

Off-balance-sheet lease commitments that haven't started yet grew again, to $308 million

As of December 31, 2022, Coupang had entered into operating leases that have not yet commenced, with future minimum lease payments of $308 million (up from $285 million at Q3 2022's quarter-end), none of which appear on the balance sheet - not even as a right-of-use asset - because lease accounting only requires recognition once a lease actually commences. These leases run 1 to 10 years, and the growing gap between this figure and the on-balance-sheet lease liability is worth tracking as fulfillment-center expansion continues.

Total minimum contractual commitments rose to $3.975 billion, continuing 2022's growth trend

Total minimum contractual commitments (unconditional purchase obligations, long-term debt including interest, and operating lease payments, all undiscounted) reached $3.975 billion as of December 31, 2022, up from the $3.744 billion flagged last quarter. Of the $814 million due within the next 12 months, operating leases ($409.6 million) are now the largest single component, ahead of purchase obligations ($249.8 million) and long-term debt including interest ($155.0 million) - a reminder that Coupang's near-term contractual burden is increasingly a leasing story, not just a debt story.

Target Valuation Range

EV $23.4 billion, ~1.14x EV/Revenue. Bottom line: the stock is cheaper relative to Coupang's own operating performance than at any point this site has tracked, and that gap - not any single number in isolation - is this filing's real valuation story.

Coupang closed FY2022 (December 30, 2022, the last trading day of the year) at $14.71, down from $29.38 a year earlier - a 49.9% decline for the full year, and down 11.8% from $16.67 at the end of Q3 2022 alone. With 1,597,804,374 Class A shares and 174,802,990 Class B shares outstanding (1,772,607,364 total) at year-end, that implies a market capitalization of approximately $26.1 billion, down from $29.5 billion three months earlier and $51.5 billion at the end of 2021.

Using cash and cash equivalents of $3.509 billion against total debt (short-term borrowings, current portion of long-term debt, and long-term debt) of approximately $842.2 million, net cash comes to roughly $2.667 billion, putting enterprise value at approximately $23.4 billion.

Market cap → enterprise value	Q4 2022
Share price (period-end)	$14.71
Shares outstanding (Class A + B)	1,772,607,364
Market capitalization	$26.1 billion
Net cash (cash & equivalents less total debt)	$2.667 billion
Enterprise value	$23.4 billion

EV/Revenue sanity check	Q3 2022	Q4 2022	Change
Enterprise value	$27.3 billion	$23.4 billion	down
EV/Revenue	1.34x	1.14x	down

• EV/Revenue^» using full-year 2022 revenue ($20.583 billion): ~1.14x, down from Q3 2022's ~1.34x (annualized quarterly basis) and far below the ~2.4x this site recorded at the end of 2021.
• Using Q4 2022's implied revenue annualized ($5.327 billion × 4 = $21.31 billion): ~1.10x, essentially the same read either way.

DCF and reverse DCF (illustrative only): eight quarters of public-company data now cover a clean run from Q3 2021 (the last quarter untouched by the fire) through Q4 2022, including two consecutive quarters of accelerating GAAP profitability. Checking this quarter against Q3's revised base case:

Scenario	Assumption / outcome
Current (period-end close)	Actual EV/Revenue this quarter, for reference: 1.14x
Q3 base case	The Q3 base case called for Product Commerce to hold its newly profitable run-rate, Developing Offerings' loss to keep narrowing, free cash flow's outflow to narrow, and the multiple to hold in the 1.2-1.4x range. The operating half came through cleanly - Product Commerce held and grew, Developing Offerings narrowed further, free cash flow swung meaningfully positive in Q4. The multiple half did not: instead of holding at 1.2-1.4x, it compressed to ~1.10-1.14x, the opposite of what the base case expected.
Bear case for next quarter	Bear case for next quarter: the operating improvement plateaus rather than continuing to accelerate (Q4's jump was partly a seasonal holiday effect - see Key Operational Metrics above - and reverts in Q1), the newly-disclosed securities litigation (see Beyond the Usual above) develops into a real financial exposure, and the multiple compresses further as 2023's macro environment for growth-stock multiples stays difficult.
Base case for next quarter	Base case for next quarter: Product Commerce holds its profitable run-rate without Q4's seasonal boost, Developing Offerings' loss keeps narrowing at a similar pace, free cash flow reverts toward Q1-Q3's outflow pattern (Q4's positive swing was seasonal working capital, not a new steady state), and the multiple stabilizes somewhere in the 1.0-1.2x range rather than continuing to compress.
Bull case for next quarter	Bull case for next quarter: Q1 2023 holds a meaningful share of Q4's per-customer revenue gain rather than reverting fully, the securities litigation is resolved or narrowed early, and the market re-rates the stock back toward 1.3-1.5x on evidence that two consecutive record-profit quarters were the start of a durable trend rather than a peak-season high-water mark - which is exactly the case this filing's operating numbers make, even if the stock price doesn't yet reflect it.

---